SNSteffie K. Naber

Steffie K. Naber

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Steffie K. Naber has a total of 102 co-authors. Here are the top co-authors by number of shared publications:

  • Marjolein van Ballegooijen

    Erasmus Medical Center—University Medical Center, Department of Public Health, Rotterdam, the Netherlands

    14 shared publications
  • Corine Penning

    Department of Public Health, Erasmus MC, University Medical Center, 3000 CA Rotterdam, Netherlands

    7 shared publications
  • Iris Lansdorp-Vogelaar

    Department of Public Health Erasmus University Medical Center Rotterdam The Netherlands

    7 shared publications
  • Ann G. Zauber

    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center , New York, NY

    5 shared publications
  • Inge M.C.M. de Kok

    Erasmus Medical Center—University Medical Center, Department of Public Health, Rotterdam, the Netherlands

    5 shared publications
  • Kirsten Rozemeijer

    Department of Public Health, Erasmus MC, University Medical Center, 3000 CA Rotterdam, Netherlands

    5 shared publications

Latest Publications

  • Open Access

    The Differential Risk of Cervical Cancer in HPV-Vaccinated and -Unvaccinated Women: A Mathematical Modeling Study

    by Emi Naslazi, Jan A.C. Hontelez, Steffie K. Naber, Marjolein van Ballegooijen, Inge M.C.M. de Kok

    Background: With increased uptake of vaccination against human papillomavirus (HPV), protection against cervical cancer will also increase for unvaccinated women, due to herd immunity. Still, the differential risk between vaccinated and unvaccinated women might warrant a vaccination-status–screening approach. To understand the potential value of stratified screening protocols, we estimated the risk differentials in HPV and cervical cancer between vaccinated and unvaccinated women. Methods: We used STDSIM, an individual-based model of HPV transmission and control, to estimate the HPV prevalence reduction over time, after introduction of HPV vaccination. We simulated scenarios of bivalent or nonavalent vaccination in females-only or females and males, at 20% coverage increments. We estimated relative HPV-type–specific prevalence reduction compared with a no-vaccination counterfactual and then estimated the age-specific cervical cancer risk by vaccination status. Results: The relative cervical cancer risk for unvaccinated compared with vaccinated women ranged from 1.7 (bivalent vaccine for females and males; 80% coverage) to 10.8 (nonavalent vaccine for females-only; 20% coverage). Under 60% vaccination coverage, which is a representative coverage for several western countries, including the United States, the relative risk (RR) varies between 2.2 (bivalent vaccine for females and males) and 9.2 (nonavalent vaccine for females). Conclusions: We found large cervical cancer risk differences between vaccinated and unvaccinated women. In general, our model shows that the RR is higher in lower vaccine coverages, using the nonavalent vaccine, and when vaccinating females only. Impact: To avoid a disbalance in harms and benefits between vaccinated and unvaccinated women, vaccination-based screening needs serious consideration.


  • Open Access

    Colorectal cancer screening within colonoscopy capacity constraints: can FIT-based programmes save more lives by trading-off more sensitive test cut-offs against longer screening intervals?

    by Ethna McFerran, James F. O’mahony, Steffie Naber, Linda Sharp, Ann G. Zauber, Iris Lansdorp-Vogelaar, Frank Kee

    Introduction: Colorectal cancer (CRC) prevention programmes using faecal immunochemical testing (FIT) as the primary screen typically rely on colonoscopy for secondary and surveillance testing. Colonoscopy capacity is an important constraint, limiting the number of primary tests offered. Many European programmes lack sufficient colonoscopy capacity to provide optimal screening intensity regarding screening age ranges, intervals and FIT cut-offs. It is currently unclear how to optimise programmes within colonoscopy capacity constraints. Design: The MISCAN-Colon microsimulation model was used to determine if more effective CRC screening programmes can be identified within existing colonoscopy capacity. The model assessed 525 strategies of varying screening intervals, age ranges and FIT cut-offs, including previously unevaluated 4 and 5 year screening intervals. These strategies were compared with policy decisions taken in Ireland to provide CRC screening within available colonoscopy capacity. Outcomes estimated net costs, quality-adjusted-life-years and required colonoscopy numbers. The optimal strategies within finite colonoscopy capacity constraints were identified. Results: Combining a reduced FIT cut-off of 10 µg Hb/g, an extended screening interval of 4 years and an age range of 60-72 years requires 6% fewer colonoscopies, reduces net costs by 23% while preventing 15% more CRC deaths and saving 16% more QALYs relative to current policy. Conclusion: Previously overlooked longer screening intervals may balance optimal cancer prevention with finite colonoscopy capacity constraints. Simple changes to screening configurations could save lives, reduce costs, and relieve colonoscopy capacity pressures. These findings are directly relevant to CRC screening programmes across Europe that employ FIT-based testing and face colonoscopy capacity constraints.

  • Open Access

    Cost‐effectiveness of HPV‐based cervical screening based on first year results in the Netherlands: a modelling study

    by Erik E.L. Jansen, Steffie K. Naber, Clare A. Aitken, Harry J. de Koning, Marjolein van Ballegooijen, Inge M.C.M. de Kok

    Objective: We aim to compare the cost‐effectiveness of the old cytology programme with the new high‐risk human papillomavirus (hrHPV) screening programme, using performance indicators from the new Dutch hrHPV screening programme.Design: Model‐based cost‐effectiveness analysis.Setting: The Netherlands.Population: Dutch 30‐year‐old unvaccinated females followed up lifelong.Methods: We updated the microsimulation screening analysis (MISCAN) model using the most recent epidemiological and screening data from the Netherlands. We simulated both screening programmes, using the screening behaviour and costs observed in each programme. Sensitivity analyses were performed on screening behaviour, utility losses and discount rates.Main outcome measures: Cervical cancer incidence and mortality rates, number of screening tests and repeat tests, colposcopy referrals by lesion grade, costs from a societal perspective, quality‐adjusted life years (QALYs) gained and cost‐effectiveness.Results: The new Dutch cervical cancer screening programme decreased the cervical cancer mortality by 4% and the incidence by 1% compared with the old programme. Colposcopy referrals of women without cervical intra‐epithelial neoplasia grade 2 or worse, increased by 172%, but 13% more QALYs were still achieved. Total costs were reduced by 21%, mainly due to fewer screening tests. Per QALY gained, the hrHPV programme cost 46% less (€12,225) than the cytology programme (€22,678), and hrHPV‐based screening remained more cost‐effective in all sensitivity analyses.Conclusions: The hrHPV‐based screening programme was found to be more effective and cost‐effective than the cytology programme. Alternatives for the current triage strategy should be considered to lower the number of unnecessary referrals.Tweetable First results after implementation confirm that HPV screening is more cost‐effective than cytology screening.


  • Cost-Effectiveness of Personalized Screening for Colorectal Cancer Based on Polygenic Risk and Family History

    by Dayna R. Cenin, Steffie K. Naber, Anne C. de Weerdt, Mark A. Jenkins, David B. Preen, Hooi C. Ee, Peter C. O'LEary, Iris Lansdorp-Vogelaar

    Background: There is growing evidence for personalizing colorectal cancer screening based on risk factors. We compared the cost-effectiveness of personalized colorectal cancer screening based on polygenic risk and family history to uniform screening. Methods: Using the MISCAN-Colon model, we simulated a cohort of 100 million 40-year-olds, offering them uniform or personalized screening. Individuals were categorized based on polygenic risk and family history of colorectal cancer. We varied screening strategies by start age, interval and test and estimated costs, and quality-adjusted life years (QALY). In our analysis, we (i) assessed the cost-effectiveness of uniform screening; (ii) developed personalized screening scenarios based on optimal screening strategies by risk group; and (iii) compared the cost-effectiveness of both. Results: At a willingness-to-pay threshold of $50,000/QALY, the optimal uniform screening scenario was annual fecal immunochemical testing (FIT) from ages 50 to 74 years, whereas for personalized screening the optimal screening scenario consisted of annual and biennial FIT screening except for those at highest risk who were offered 5-yearly colonoscopy from age 50 years. Although these scenarios gained the same number of QALYs (17,887), personalized screening was not cost-effective, costing an additional $428,953 due to costs associated with determining risk (assumed to be $240 per person). Personalized screening was cost-effective when these costs were less than ∼$48. Conclusions: Uniform colorectal cancer screening currently appears more cost-effective than personalized screening based on polygenic risk and family history. However, cost-effectiveness is highly dependent on the cost of determining risk. Impact: Personalized screening could become increasingly viable as costs for determining risk decrease.


  • Open Access

    Optimizing Management of Patients With Barrett’s Esophagus and Low-Grade or No Dysplasia Based on Comparative Modeling

    by Amir-Houshang Omidvari, Ayman Ali, William D. Hazelton, Sonja Kroep, Minyi Lee, Steffie K. Naber, Brianna N. Lauren, Sassan Ostvar, Ellen Richmond, Chun Yin Kong, et al.


  • Open Access

    WITHDRAWN: Cost-effectiveness of inactivated influenza vaccination in children with medical risk conditions in the Netherlands

    by Steffie K. Naber, Patricia C.J.L. Bruijning-Verhagen, Marieke L.A. de Hoog, Anoukh van Giessen

  • Open Access

    Cost-Effectiveness of Risk-Stratified Colorectal Cancer Screening Based on Polygenic Risk: Current Status and Future Potential

    by Steffie K Naber, Suman Kundu, Karen M Kuntz, W David Dotson, Marc S Williams, Ann G Zauber, Ned Calonge, Doris T Zallen, Theodore G Ganiats, Elizabeth M Webber, et al.

    Background: Although uniform colonoscopy screening reduces colorectal cancer (CRC) mortality, risk-based screening may be more efficient. We investigated whether CRC screening based on polygenic risk is a cost-effective alternative to current uniform screening, and if not, under what conditions it would be.Methods: The MISCAN-Colon model was used to simulate a hypothetical cohort of US 40-year-olds. Uniform screening was modeled as colonoscopy screening at ages 50, 60, and 70 years. For risk-stratified screening, individuals underwent polygenic testing with current and potential future discriminatory performance (area under the receiver-operating curve [AUC] of 0.60 and 0.65–0.80, respectively). Polygenic testing results were used to create risk groups, for which colonoscopy screening was optimized by varying the start age (40–60 years), end age (70–85 years), and interval (1–20 years).Results: With current discriminatory performance, optimal screening ranged from once-only colonoscopy at age 60 years for the lowest-risk group to six colonoscopies at ages 40–80 years for the highest-risk group. While maintaining the same health benefits, risk-stratified screening increased costs by $59 per person. Risk-stratified screening could become cost-effective if the AUC value would increase beyond 0.65, the price per polygenic test would drop to less than $141, or risk-stratified screening would lead to a 5% increase in screening participation.Conclusions: Currently, CRC screening based on polygenic risk is unlikely to be cost-effective compared with uniform screening. This is expected to change with a greater than 0.05 increase in AUC value, a greater than 30% reduction in polygenic testing costs, or a greater than 5% increase in adherence with screening.


  • Open Access

    Cost-effectiveness of a multitarget stool DNA test for colorectal cancer screening of Medicare beneficiaries

    by Steffie K Naber, Amy B Knudsen, Ann G Zauber, Carolyn M Rutter, Sara E Fischer, Chester J Pabiniak, Brittany Soto, Karen M Kuntz, Iris Lansdorp-Vogelaar

    In 2014, the Centers for Medicare and Medicaid Services (CMS) began covering a multitarget stool DNA (mtSDNA) test for colorectal cancer (CRC) screening of Medicare beneficiaries. In this study, we evaluated whether mtSDNA testing is a cost-effective alternative to other CRC screening strategies reimbursed by CMS, and if not, under what conditions it could be. We use three independently-developed microsimulation models to simulate a cohort of previously unscreened US 65-year-olds who are screened with triennial mtSDNA testing, or one of six other reimbursed screening strategies. Main outcome measures are discounted life-years gained (LYG) and lifetime costs (CMS perspective), threshold reimbursement rates, and threshold adherence rates. Outcomes are expressed as the median and range across models. Compared to no screening, triennial mtSDNA screening resulted in 82 (range: 79–88) LYG per 1,000 simulated individuals. This was more than for five-yearly sigmoidoscopy (80 (range: 71–89) LYG), but fewer than for every other simulated strategy. At its 2017 reimbursement rate of $512, mtSDNA was the most costly strategy, and even if adherence were 30% higher than with other strategies, it would not be a cost-effective alternative. At a substantially reduced reimbursement rate ($6–18), two models found that triennial mtSDNA testing was an efficient and potentially cost-effective screening option. Compared to no screening, triennial mtSDNA screening reduces CRC incidence and mortality at acceptable costs. However, compared to nearly all other CRC screening strategies reimbursed by CMS it is less effective and considerably more costly, making it an inefficient screening option.


  • 519 – The Age to Stop Endoscopic Surveillance of Barrett's Esophagus: A Cost-Effectiveness Analysis

    by Amir-Houshang Omidvari, Minyi Lee, Steffie K. Naber, William D. Hazelton, Chung Yin Kong, Ellen Richmond, Joel H. Rubenstein, Georg Luebeck, John M. Inadomi, Chin Hur, et al.

  • Cost Effectiveness of Age-Specific Screening Intervals for People With Family Histories of Colorectal Cancer

    by Steffie K. Naber, Karen M. Kuntz, Nora B. Henrikson, Marc S. Williams, Ned Calonge, Katrina A.B. Goddard, Doris T. Zallen, Theodore G. Ganiats, Elizabeth M. Webber, A. Cecile J.W. Janssens, et al.